期刊
CANCER TREATMENT REVIEWS
卷 99, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2021.102256
关键词
PARP; Homologous recombination repair; Non-small cell lung cancer; Small cell lung cancer; Malignant pleural mesothelioma
类别
The evaluation of the HRR status is becoming an important predictive biomarker for PARP inhibition in various tumor types, particularly in thoracic malignancies. Clinical trials are currently being conducted to explore the efficacy of novel PARPi combinations in patients with lung cancer and malignant pleural mesothelioma, taking advantage of the deeper understanding of HRR-deficient tumors and the development of new targeted and immunotherapeutic agents.
The evaluation of the homologous recombination repair (HRR) status is emerging as a predictive tumor agnostic biomarker for poly (ADP-ribose) polymerase (PARP) inhibition across different tumor types and testing for HRRsignature is currently a developing area with promising therapeutic implications. Treatment with PARP inhibitors (PARPi) either as single agent or in combination with chemotherapy have shown so far limited activity in patients with thoracic malignancies. A deeper understanding of the biological background underlying HRRdeficient tumors, along with the recent advent of new effective targeted and immunotherapeutic agents, prompted the design of a new generation of clinical trials investigating novel PARPi-combinations in patients with lung cancer as well as malignant pleural mesothelioma. In this review we briefly summarize the biological basis of the DNA damage response pathway inhibition and provide an updated and detailed overview of clinical trials testing different PARPi-combinations strategies in patients with thoracic malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据